Acurx Pharmaceuticals Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance

Acurx Pharmaceuticals has approved a 1-for-20 reverse stock split to increase the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement. The split will reduce the number of outstanding shares from 30.8 million to 1.5 million. Stockholders holding physical certificates will need to exchange them for electronic shares, while those with electronic shares and broker accounts will not need to take action. The split is expected to take effect on August 5, 2025.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has announced a 1-for-20 reverse stock split, effective August 4, 2025, at 4:01 p.m. ET. The company aims to increase the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement. The reverse stock split will reduce outstanding shares from approximately 30.7 million to 1.5 million.

The reverse stock split will legally take effect at 4:01 p.m. ET on August 4, 2025, and the stock will begin trading on a split-adjusted basis on August 5, 2025, under the same ticker "ACXP" but with a new CUSIP number (00510M 203). Stockholders will receive cash payments for fractional shares based on the closing price on August 1, 2025. Proportional adjustments will be made to stock options, warrants, and shares under incentive plans.

Stockholders holding physical certificates will need to exchange them for electronic shares, while those with electronic shares and broker accounts will not need to take action. The split is expected to take effect on August 5, 2025.

References:
[1] https://www.stocktitan.net/news/ACXP/acurx-pharmaceuticals-inc-announces-reverse-stock-v39hzda81k8x.html
[2] https://www.nasdaq.com/press-release/aqua-metals-announces-reverse-stock-split-2025-07-31
[3] https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-announces-reverse-stock-split-302518702.html